Transcriptomic Classification of Pituitary Neuroendocrine Tumors Causing Acromegaly

Julia Rymuza 1,†, Paulina Kober 1,†, Natalia Rusetska 1, Beata J. Mossakowska 1, Maria Maksymowicz 2, Aleksandra Nyc 2, Szymon Baluszek 1, Grzegorz Zieliński 3, Jacek Kunicki 4 and Mateusz Bujko 1,*,†

1 Department of Molecular and Translational Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland
2 Department of Cancer Pathomorphology, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland
3 Department of Neurosurgery, Military Institute of Medicine, 04-141 Warsaw, Poland
4 Department of Neurosurgery, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland
* Correspondence: mateusz.bujko@pib-nio.pl
† These authors contributed equally to this work.

Abstract: Acromegaly results from growth hormone hypersecretion, predominantly caused by a somatotroph pituitary neuroendocrine tumor (PitNET). Acromegaly-causing tumors are histologically diverse. Our aim was to determine transcriptomic profiles of various somatotroph PitNETs and to evaluate clinical implication of differential gene expression. A total of 48 tumors were subjected to RNA sequencing, while expression of selected genes was assessed in 134 tumors with qRT-PCR. Whole-transcriptome analysis revealed three transcriptomic groups of somatotroph PitNETs. They differ in expression of numerous genes including those involved in growth hormone secretion and known prognostic genes. Transcriptomic subgroups can be distinguished by determining the expression of marker genes. Analysis of the entire cohort of patients confirmed differences between molecular subtypes of tumors. Transcriptomic group 1 includes ~20% of acromegaly patients with GNAS mutations-negative, mainly densely granulated tumors that co-express GIPR and NR5A1 (SF-1). SF-1 expression was verified with immunohistochemistry. Transcriptomic group 2 tumors are the most common (46%) and include mainly GNAS-mutated, densely granulated somatotroph and mixed PitNETs. They have a smaller size and express favorable prognosis-related genes. Transcriptomic group 3 includes predominantly sparsely granulated somatotroph PitNETs with low GNAS mutations frequency causing ~35% of acromegaly. Ghrelin signaling is implicated in their pathogenesis. They have an unfavorable gene expression profile and higher invasive growth rate.

Keywords: neuroendocrine pituitary tumors; somatotropinoma; acromegaly; growth hormone; gene expression; transcriptome

1. Introduction

Acromegaly is a severe and life-threatening disease caused by persistent excess of growth hormone (GH), which stimulates synthesis and secretion of the insulin-like growth factor-1 (IGF-1). In the majority (95%) of patients, acromegaly is caused by sporadic GH-secreting pituitary neuroendocrine tumor (PitNET). High IGF-1 level promotes cell proliferation, inhibits apoptosis, and causes most of the clinical symptoms of acromegaly, ranging from subtle to severe, including limb hypertrophy, soft tissue edema, arthralgia, prognathism and hyperhidrosis to frontal bone hypertrophy, diabetes mellitus, hypertension, and respiratory and heart failure. Excessive body growth and gigantism may develop when a somatotroph tumor develops in young patients before closing the epiphyses of long bones [1].
Acromegaly is a particular disease entity that is generally treated with somatostatin analogs and surgery. However, PitNETs that cause clinical symptoms are quite heterogeneous, varying in terms of pathomorphological characteristics, radiological imaging results, invasiveness, and molecular features [2,3]. Most of somatotroph tumors express GH and PIT-1 transcription factor and are further divided into sparsely and densely granulated (SG and DG, respectively) with electron microscopy-based evaluation or anti-cytokeratin staining. These two types of somatotroph tumors differ in magnetic resonance imaging (MRI) features and clinical course of the disease [4]. Acromegaly can also be caused by mammosomatotroph and mature plurihormonal tumors, characterized by expression of GH and additional hormones (prolactin (PRL) or PRL and thyroid-stimulating hormone (TSH)), respectively. Additionally, it may be caused by mixed somatotroph–lactotroph tumors (composed of two distinct populations of somatotroph and lactotroph tumor cells), poorly-differentiated Pit1-lineage tumors, and acidophil stem cell tumors features [2,3]. SG somatotroph PitNETs and plurihormonal PIT-1 positive PitNETs are categorized as high-risk tumors due to characteristics of aggressiveness including invasive growth and higher recurrence rate [5].

The most common molecular changes in somatotroph tumors are activating mutations in GNAS gene, which encodes a stimulatory subunit of heterotrimeric G protein. These mutations are present in approximately 40% of somatotroph PitNETs [6]. They cause hyperactivation of cAMP-dependent pathways and, consequently, both increased secretion of GH and proliferation of somatotropic cells [7]. Clinical significance of GNAS mutations is unclear; however, they are certainly more common in DG than in SG tumors [8].

Recently, a subset of somatotroph PitNETs with elevated expression of gastric inhibitory polypeptide receptor (GIPR) was identified [9,10]. In these tumors GIPR expression is considered to additionally stimulate cAMP pathway causing paradoxical GH response to glucose intake [11]. These tumors were suggested to constitute a separate molecular subgroup as they differ in epigenetic profile and high GIPR expression is mutually exclusive with GNAS mutations [12].

Considering the complex nature of the clinical and pathological spectrum of PitNETs causing acromegaly we aimed to investigate gene expression in somatotroph tumors to verify whether transcriptomic profiles correspond to current histological/clinical classification.

2. Materials and Methods
2.1. Patients and Tissue Samples

This study included 134 patients with biochemically confirmed acromegaly that were treated with transsphenoidal surgery in two specialized centers: the Department of Neurosurgery, Military Institute of Medicine, Warsaw and the Department of Neurosurgery, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw in the years 2013–2020. Diagnostic criteria of acromegaly based on clinical characteristics, increased serum IGF-1 levels, and non-suppressible GH after oral glucose tolerance test (OGTT) in patients with no OGTT contraindications were used. All patients received somatostatin receptors ligands (SRLs) treatment (octreotide or lanreotide) before surgery following the recommendations of Polish Society of Endocrinology [13]. Invasive growth was determined based on preoperative MRI using Knosp classification. Tumors scored with Knosp grades 0–2 were considered noninvasive, while those with Knosp grade 3 and 4 were considered invasive [14].

Each tumor sample was divided in three parts. One of them was snap frozen in liquid nitrogen and stored for molecular analysis and the other two were preserved for histopathological evaluation, including immunohistochemical staining and ultrastructural analysis with electron microscopy. Pathomorphological diagnosis was based on evaluation of the immunoexpression of pituitary hormones (GH, PRL, ACTH, TSH, FSH, LH, α-subunit) and Ki-67, as well as assessment of ultrastructural status (sparsely vs. densely granulated tumors). Expression of PIT-1 transcription factor was confirmed with immunohistochemical staining retrospectively since a large proportion of the tumors were originally diagnosed
with WHO 2014 criteria that did not comprise evaluation of transcription factors. Overall patients’ characteristics are presented in Table 1.

Table 1. Summary of demographical and clinical features of patients with acromegaly.

| Clinical Feature | All Acromegaly Patients | Patients Included In RNA-Seq |
|------------------|-------------------------|-----------------------------|
| **Number of patients** | n = 134 | n = 48 |
| **Sex** | | |
| Female | 73/134 (54.5%) | 30/48 (62.5%) |
| Male | 61/134 (45.5%) | 18/48 (37.5%) |
| **Age at surgery (years; median (range))** | 44 (22–74) | 39 (22–74) |
| **GH (µg/dL; median (range))** | 11.8 (0.4–171) * | 9.77 (0.89–177) |
| **IGF-1 (µg/dL; median (range))** | 735 (166–1836) ** | 698 (166–1600) |
| **Tumor size—max. diameter (mm; median (range))** | 16 (5–77) | 18 (5.1–77) |
| **Invasive tumor growth** | | |
| Invasive tumors (Knosp grade III, IV) | 39/134 (29.1%) | 22/48 (45.8%) |
| Noninvasive tumors (Knosp grade 0, I, II) | 95/134 (70.9%) | 26/48 (54.2%) |
| **Ultrastructural evaluation** | | |
| Sparsely granulated (SG tumors) | 43/134 (32%) | 24/48 (50%) |
| Densely granulated (DG tumors) | 91/134 (67.9%) | 24/48 (50%) |
| **Diagnosis** | | |
| DG somatotroph tumors | 66/134 (49.25%) | |
| SG somatotroph tumors | 43/134 (31.3%) | 24/48 (50%) |
| Mixed GH/PRL tumors | 18/134 (11.9%) | 24/48 (50%) |
| Mammosomatotroph tumors (GH/PRL) | 1/134 (0.75%) | - |
| Plurihormonal tumors (GH/PRL/TSH) | 1/134 (0.75%) | - |
| Plurihormonal tumors (GH/LH) | 5/134 (3.7%) | - |

* The exact value was not available for 23 patients; ** The exact value was not available for 25 patients.

The study was approved by the local Ethics Committee of Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw, Poland. Each patient provided informed consent for the use of tissue samples for scientific purposes.

DNA and total RNA from tumor samples were isolated with AllPrep DNA/RNA/miRNA Universal Kit (QIAGEN) and stored at −70 °C.

2.2. Testing for GNAS Mutation Status

The presence of GNAS point mutation (exons 7 and 8) was assessed with Sanger sequencing in 134 tumor samples. DNA was amplified in PCR with FastStart Taq DNA Polymerase (Roche Diagnostics, Mannheim, Germany) using GeneAmp 9700 PCR system (Applied Biosystems, Foster City, CA, USA). PCR product was purified with ExoStar (GE Healthcare Life Sciences, Pittsburgh, PA, USA), labeled with BigDye Terminator v.3.1 (Applied Biosystems), and analyzed by capillary electrophoresis using ABI PRISM 3300 Genetic Analyzer (Applied Biosystems). PCR primers' sequences are provided in Supplementary Table S1.

2.3. RNA Sequencing

A total of 48 tumor samples were subjected to RNA sequencing (RNA-seq). We included pure somatotroph PitNETs (mixed GH/PRL, mammosomatotroph, or plurihormonal tumors were not included) with equal proportions of SD and DG tumors. Library preparation was performed with 1 µg RNA from each sample using NEBNext Ultra II Directional RNA Library Prep Kit for Illumina. NEBNext rRNA Depletion Kit was used for ribosomal depletion. The quality of libraries was assessed using the Agilent Bioanalyzer

...
2100 system (Agilent Technologies, Santa Clara, CA, USA). Libraries were then sequenced on an Illumina NovaSeq 6000 platform, and 150-bp paired-end reads were generated. A minimum of 30 M read pairs per sample were generated. Sequencing was performed by Eurofins Genomics service.

2.4. Analysis of RNA-Seq Results

Quality control of raw reads was conducted using FastQC [15]. Raw reads were mapped to the human reference genome GRCh37/hg19 with HISAT2 [16]. The raw un-normalized count matrix was generated using featureCounts [17] with gene features from GENCODE (v39) and imported to DESeq2 [18]. Low-expression genes (genes with less than five sequencing reads in less than 25% of samples) were excluded from further analysis. Filtered matrix was normalized using DESeq2 [18] and used for sample clustering with k-means algorithm (R package cluster [19]) and hierarchical clustering (Manhattan distance and ward.D agglomeration, R library stats). Analysis of genes differentially expressed between clusters (transcriptomic groups) was performed using DESeq2 [18]. Differentially expressed genes (DEGs) were defined as those with adjusted \( p \)-value < 0.05 and fold change value (|FC|) > 2. Gene set enrichment (GSE) analysis was conducted with fgsea [20]. Additionally, marker genes for each group were detected using R package MGFR.

2.5. Quantitative Reverse Transcription PCR (qRT-PCR) Gene Expression Analysis

One microgram of RNA was subjected to reverse transcription with Transcriptor First Strand cDNA Synthesis Kit (Roche Diagnostics, Mannheim, Germany). qRT-PCR reaction was carried out in 384-well format using 7900HT Fast Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) and Power SYBR Green PCR Master Mix (Thermo Fisher Scientific, Waltham, MA, USA) in a volume of 5 \( \mu \)L, containing 2.25 pmol of each primer. The samples were amplified in triplicates. GAPDH and SDHA served as reference genes. Delta Ct method was used to calculate relative expression level with geometric mean of reference genes Ct value for normalization. PCR primers’ sequences are presented in Supplementary Table S1.

2.6. Immunohistochemical Staining

Immunohistochemical staining (IHC) was performed on 4 \( \mu \)m FFPE tumor sections with the use of Envision Detection System (no. K500711-2, DAKO, Glostrup, Denmark). Tissue samples were deparaffinized with xylene and rehydrated in a series of ethanol solutions of decreasing concentration. Heat-induced epitope retrieval was carried out in a Target Retrieval Solution pH 9 (DAKO) in a 96 °C water bath, for 30 min. Tumor sections were treated with a blocker of endogenous peroxidase (DAKO) for 5 min and then incubated for 1 h with the primary antibody anti-Pit-1 (clone D-7; dilution 1:2000) (sc-393943; Santa Cruz Biotechnology, Dallas, TX, USA) or ant-SF1 (clone A1; dilution 1:500) (sc-393592; Santa Cruz Biotechnology). The color reaction product was developed with 3,3′-diaminobenzidine tetrahydrochloride (DAKO) as a substrate; hematoxylin counter-staining was applied for nuclear contrast.

2.7. Statistical Analysis and Data Visualization

Two-sided Mann–Whitney U-test was used for analysis of continuous variables. The Spearman correlation method was used for correlation analysis. Significance threshold of \( \alpha = 0.05 \) was adopted. Data were analyzed and visualized using GraphPad Prism 6.07 (GraphPad Software) and R environment. R libraries such as ggplot2 [21] and plotly [22] were used for visualization. Moreover, scaled normalized RNA-seq read counts were visualized on KEGG pathway graph using pathview [23]. In pathview visualization, the median of scaled normalized RNA-seq read counts for multiple genes were presented for the pathway elements if it was composed of more than one gene, according to KEGG Pathway Database annotation. Hsa04935 KEGG pathway was used.
3. Results
3.1. Incidence of GNAS Mutations

First, we determined GNAS mutational status in tumor samples in the entire cohort of patients. The missense mutations were identified in 52/134 (38.8%) patients. A total of 40 patients harbored mutations in exon 8 including 35 variants c.C601T:p.R201C, 4 c.A680G:p.Q227R, and 2 c.C601A:p.R201S. A total of 12 patients had mutations in exon 9 including seven variants c.A680AT:p.Q227L and five c.A680G:p.Q227R. We did not observe significant relationship between GNAS mutation and demographical/clinical features including patients’ age, gender, pathological diagnosis, invasiveness status, and tumor size.

3.2. Whole Transcriptome Analysis

A total of 48 tumor samples were successfully processed. An average of 87,347,293 reads per sample were generated with an average 90.79% reads mapped to UCSC hg19 reference genome. The sequencing reads were mapped to 19,631 human protein-coding genes, and 16,096 mapped protein-coding genes remained for inclusion in subsequent analyses after low-expression genes were filtered out.

Data-dimensionality reduction analysis including principal component analysis (PCA) and uniform manifold approximation and projection (UMAP) clearly indicated the presence of three separate transcriptomic groups of tumor samples with groups 1 and 2 being more similar to each other than to the third group (Figure 1A). The same pattern was observed in hierarchical clustering analysis where three basic branches of clustering tree corresponded to transcriptomic groups observed in PCA and UMAP results (Figure 1B). Nearly the same clustering results were observed regardless of the number of differentially expressed genes included in the analysis. The results for 1%, 10%, and 20% of most differentially expressed genes are presented in Supplementary Figure S1. The preliminary analysis of clinical data for discovery set of 48 samples revealed notable differences between three identified transcriptomic groups. Group 1 included GNAS wild-type (GNASwt) DG tumors (except for one GNASwt, SG tumor), group 2 included mainly DG tumors with a high proportion of samples with GNAS mutation, and group 3 included basically SG tumors with a low percentage of GNAS-mutated (GNASmut) ones.

We determined the genes that are differentially expressed between each of the transcriptomic groups by comparing each group with the remaining groups separately (group 1 vs. group 2, group 2 vs. group 3, and group 2 vs. group 3). We found that paired groups differ in the expression of high number of genes. Specifically, 1007 differentially expressed genes (DEGs) that met criteria |FC| > 2 and adjusted p-value < 0.05 were found when comparing groups 1 and 2, 2403 DEGs were identified when comparing groups 1 and 3, and 1685 DEGs were found in comparison of groups 2 and 3. Results of differential analysis are presented in Figure 1B. The lists of differentially expressed genes are reported in Supplementary Table S2.

The functional implications of the difference in gene expression were investigated with GSE analysis with Gene Ontology (GO) including GO Biological Processes and GO Molecular function. The analysis resulted in the identification of a large number of significantly enriched GO terms. The most significantly enriched GO Biological Processes, according to the highest significance level were the terms related to G-protein signaling, ion transport, cellular adhesion, and differentiation, while the most enriched GO Molecular function terms were those related to signaling and ion transport. The top 10 most enriched terms for each comparison are presented in Figure 2; all significantly enriched terms are listed in Supplementary Table S3.
3.3. Differences in the Expression of Genes Involved in GH Secretion Pathway

With a given high number of DEGs we paid a special attention to those that are related to GH secretion. According to literature data growth hormone secretion is primarily induced by hypothalamic somatoliberin (GHRH) as well as by ghrelin and GIP through activation of the corresponding membrane receptor on somatotroph cells. Interestingly, we found that the three identified transcriptomic groups of somatotroph PitNETs differ significantly in the expression of genes coding for each receptor. Tumors within groups 1 and 2

**Figure 2.** Results of Gene Set Enrichment analysis. NES—normalized enrichment score.
have high expression of GHRHR (somatoliberin receptor), but lower expression of GHSR (ghrelin receptor) than tumors in group 3. Tumors in group 1, in addition to high GHRHR expression, have notably higher expression of GIPR than the two remaining transcriptomic groups. Differences were also found among genes of somatostatin and dopamine receptors that play a role in modulation of somatotroph secretory activity. Expression of SSTR3 was at a notably lower level in group 2, while a significant decrease of SSTR5 in group 1 was observed as compared to groups 2 and 3. Higher expression of dopamine receptors DRD1 and DRD2 was in turn found in group 3. Irrespectively to receptor activation, Ca\(^{2+}\) influx through voltage-gated Ca\(^{2+}\) channels (VGCCs) also plays an important role in GH secretion [24]. CACNA1C and CACNA1D encoding VGCCs were identified as expressed at significantly higher levels in groups 1 and 2 as compared to group 3. Results are presented in (Figure 3A). The signaling pathways downstream key receptors (cAMP and Phospholipase C pathways) are mediated by many proteins that are encoded by the genes that were differentially expressed between three transcriptomic groups. They include genes encoding G-proteins: GNAI1, GNAI2, adenyl cyclase ADcy1, ADcy3, ADcy4, ADcy5, ADcy7; cAMP response elements CREB1, CREB3L1, ATF2, ATF5B, ATF4, CREB, CREBP, EP300; phospholipases: PLCB2, PLCB4, PLCB1; and protein kinases: PRKCA, PRKCD, PRKCE, PRKCI, PRKCW, as well as inositol trisphosphate receptor ITPR3. Details are presented in Supplementary Figure S2A, while comprehensive representation of the expression levels of genes involved in GH secretion is presented in Figure 2, which is based on KEGG pathway (visualized with pathview, original picture available in Supplementary Figure S2B). GH1 encoding GH was also found differentially expressed, with the highest expression in transcriptomic group 1 and the lowest in group 3 (Figure 3A).

![Figure 3](image_url)

**Figure 3.** Difference in the expression of genes involved in growth hormone (GH) secretion pathway in three subtypes of somatotroph tumors. (A) Expression levels of differentially expressed genes coding for cell surface receptors involved in GH synthesis and secretion. Distribution of normalized RNA-seq read counts is presented. (B) Scaled normalized RNA-seq read counts of genes encoding each element of GH synthesis pathway were visualized on KEGG pathway with pathview. Scaled expression values (normalized RNA-seq read counts) of multiple genes were presented for the pathway elements if it is composed of more than one gene, according to KEGG Pathway Database annotation. * GIPR receptor was added manually, according to literature data [25].

### 3.4. Differences in the Expression of Known Genes Involved in Somatotropinoma Clinical Outcome

Aberrant gene expression was previously shown to be involved in acromegaly patients’ outcome and response to SRLs. Beside the role of somatostatin receptors, the role of genes involved in epithelial-mesenchymal transition, cell proliferation, and cell signaling was previously reported [26]. Transcriptomic groups of somatotroph PitNETs differed in the expression of genes related to epithelial-mesenchymal transition (EMT) that have a proven role in acromegaly, including CDH1 [27,28], SNAI2 [29], FLNA [30], ARRB1 [31,32],
RORC [33], and ESRP1 [28], but also in other genes with an important role in EMT including CDH2, CDH3, CDH11, CTNNB1, CLDN1, CLDN3, CLDN4, CLDN9, and ZAEB1 (Figure 4A). Differences between transcriptomic groups were also observed in expression levels of proliferation-related genes CCND1 [34], CDKN1B [27], and MKI67 [35] and genes involved in cell signaling TGFB1 [36] and STAT3 [37] that all have a reported role in acromegaly patients’ outcome (Figure 4B).

![Figure 3](image-url)

**Figure 3.** Difference in the expression of genes involved in growth hormone (GH) secretion pathway in three subtypes of somatotroph tumors. Distribution of normalized RNA-seq read counts are presented.

(A) Genes encoding proteins involved in epithelial-mesenchymal transition. (B) Genes related to somatotroph pituitary tumor growth.

### 3.5. Role of SF-1 (NR5A1) Transcription Factor in a Subtype of Somatotroph Tumors

We explored the expression levels of known genes encoding transcription factors specific to particular lineages of anterior pituitary cells in three identified transcriptomic groups of somatotroph tumors. A striking difference in the expression level of NR5A1 (SF-1) was observed. It is expressed at very high level in tumors from group 1 as compared to other groups. Accordingly, a significant correlation of the expression levels of proliferation-related genes CCND1 [34], CDKN1B [27], and MKI67 [35] and genes involved in cell signaling TGFB1 [36] and STAT3 [37] that all have a reported role in acromegaly patients’ outcome (Figure 4B).

We measured NR5A1 expression in somatotroph tumors of transcriptomic group 1 and gonadotroph PitNET samples (tumor samples from our previous investigation [38]) with qRT-PCR. This analysis showed that the range of NR5A1 expression in group 1 of somatotroph PitNETs and in gonadotroph PitNETs is similar (Figure 5B). Neither POU1F1 nor TBX19 were among the genes differentially expressed between tumors forming the three transcriptomic groups (Figure 5A).

Transcriptomic group 1 tumors are those with high GIPR expression. GIPR was previously found to be involved in steroidogenesis process. It induces expression of known steroidogenesis-related genes including NR5A1, STAR, and CYP11A1 [39,40]. As expected, higher expression of these genes was found in group 1 tumors as compared to each of the other groups. Accordingly, a significant correlation of the expression levels of GIPR and each of NR5A1, STAR, and CYP11A1 was found, with the highest correlation coefficient in GIPR and NR5A1 analysis (Spearman R = 0.785, p < 0.0001) (Figure 5C).

Next, we determined whether tumors of transcriptomic group 1 that express NR5A1 are positive for protein SF-1 expression as determined by immunohistochemical staining. As a result, each of the samples showed clear nuclear immuno-reactivity with antibodies against SF-1 over the entire tumor tissue sample area. The representative examples of the results of staining for PIT-1 and SF-1 are presented in Figure 5D.
We measured the expression level of nine potential markers with qRT-PCR in 48 samples to evaluate whether somatotroph tumor samples can be classified and assigned to particular transcriptomic groups by qRT-PCR-based evaluation of expression level of the marker genes. Using RNA-seq results we selected nine genes that could serve as potential classifiers. Supplementary Figure S3. We selected three marker genes (NR5A1, CCND2, and SEC23A) that met criteria of area under curve (AUC) > 0.99 and that allowed for selecting a clear threshold value. NR5A1 distinguished between transcriptomic group 1 and groups 2/3, while CCND2 and SEC23A discriminated groups 1/2 and group 3 (Figure 6B). The use of thresholds for NR5A1, CCND2, and SEC23A expression level determined by data from the RNA-seq group allows for clear categorization of nearly the entire patient cohort (Figure 6C). Six patients (4.5%) of the entire patient cohort could not be assigned to any

**Figure 5.** The expression of differentially expressed genes (DEGs) that are related to identity of anterior pituitary cells. (A) The expression levels of transcription factors specific for anterior pituitary lineages. (B) The comparison of NR5A1 (SF-1) expression in somatotroph and gonadotroph PitNETs based on qRT-PCR measurement. (C) Co-expression of GIPR and steroidogenesis-related genes that were found as differentially expressed in comparison of tumors from transcriptional group 1 with groups 2 and 3. Normalized RNA-seq read counts were analyzed. (D) Representative examples of immunohistochemical staining of somatotroph PitNETs of transcriptomic group 1 (tumors with high GIPR and NR5A1 expression) with antibodies against PIT-1 (upper panel) and SF-1 (lower panel); magnification ×200.

3.6. Difference in Clinical/Histopathological Features between Transcriptomic Groups of Somatotroph Tumors

To evaluate the differences in clinical parameters between the transcriptomic groups of somatotroph tumors we used tumor samples from the entire cohort of 134 acromegaly patients, without any intentional preselection. Unfortunately, in our study we were unable to include more than 48 RNA samples in RNA-seq procedure. Therefore, we determined whether somatotroph tumor samples can be classified and assigned to particular transcriptomic groups by qRT-PCR-based evaluation of expression level of the marker genes. We measured the expression level of nine potential markers with qRT-PCR in 48 samples that were previously included in transcriptome profiling and that were clearly categorized (Figure 6A). Using receiver operating characteristic (ROC) curve analysis we determined the value of qRT-PCR-measured expression levels as classifiers of each transcriptomic group. The results of the evaluation of the nine marker genes are presented in Supplementary Figure S3. We selected three marker genes (NR5A1, CCND2, and SEC23A) that met criteria of area under curve (AUC) > 0.99 and that allowed for selecting a clear threshold value. NR5A1 distinguished between transcriptomic group 1 and groups 2/3, while CCND2 and SEC23A discriminated groups 1/2 and group 3 (Figure 6B). The use of thresholds for NR5A1, CCND2, and SEC23A expression level determined by data from the RNA-seq group allows for clear categorization of nearly the entire patient cohort (Figure 6C). Six patients (4.5%) of the entire patient cohort could not be assigned to any
transcriptomic category due to a low expression level of each marker. These six patients were excluded from further analysis of clinical data.

Figure 6. The value of classification based on three expression markers NR5A1, CCND2, and SEC23A. (A) The expression levels of marker genes in 48 samples categorized based on RNA-seq data. Scaled qRT-PCR expression values are presented. (B) ROC curve analysis of three selected marker genes. (C) The values of marker gene expression in entire patient cohort, with classification of the samples. Six unclassified tumors were excluded. Scaled qRT-PCR expression values are presented.

The analysis of clinical data showed that in transcriptomic group 1, composed of tumors positive for NR5A1 expression, there are no mutations of GNAS. This group includes 25/128 patients (19.5%). Most of the tumors within this group were DG somatotroph PitNETs, however, five of the tumors were positive for both GH and LH upon immunohistochemical staining and were classified as plurihormonal GH/LH tumors. Transcriptomic group 2 accounted for 59/128 patients (46.1%). The vast majority of group 2 patients (66.1%) had tumors with mutations in GNAS gene, mainly determined as densely granulated. This group included DG somatotroph PitNETs, but also mixed GH/PRL tumors. Transcriptomic group 3 included 44/128 patients (34.4%) with low incidence of GNAS mutations (18% were GNASmut). The difference in proportions of GNASmut patients between transcriptomic groups was significant (Chi square test \( p < 0.0001 \)). Group 3 was composed mostly of sparsely granulated tumors as determined with electron microscopy, diagnosed mainly as SG somatotroph PitNETs. It also included seven DG tumors (10%), but no mixed or plurinominal PitNETs. In this group, a higher proportion of invasive tumors (43%, 19/44) was observed, as compared to transcriptomic groups 1 and 2 (16.6% and 20.3%, respectively) (Chi square test \( p = 0.0154 \)). Results are presented in Figure 7A. Tumors from transcriptomic group 2 were significantly smaller than those from two other groups (Figure 7B). No differences were observed in serum GH and IGF-1 levels (Figure 7B) or patients’ demographical data (age and gender) between the groups.

RNA-seq results revealed that transcriptomic groups differ in the expression level of key genes involved in GH synthesis and secretion including GHRHR, GIPR, GHSR, SST5, and DRD1 as well as GH1 encoding GH itself. Using qRT-PCR we measured expression level of these genes in the entire patient cohort categorized into three transcriptomic groups according to marker genes evaluation. Significant differences in the expression of each gene were found and confirmed the observation in whole transcriptome analysis. Groups 1 and 2 have high levels of GH1 and GHRHR. Tumors in group 1 have high GIPR expression, while those in group 3 have higher expression of ghrelin receptor (GHSR) and DRD1. A slight discrepancy was observed between qRT-PCR results of the entire cohort and data from RNA-seq in terms of SST5 expression level. PCR-based measurement showed the highest level of SST5 expression in transcriptomic group 3. Results are visualized in Figure 8.
Cells 2022, 11, x FOR PEER REVIEW 11 of 17

Figure 7. Clinical data of patients with somatotroph PitNETs categorized according to expression of marker genes into three transcriptomic groups. (A) Presentation of categorical patient characteristics. (B). Comparison of quantitative patient data including tumor size (maximal tumor diameter) as well as GH and IGF-1 plasma level. Horizontal dashed line indicates median. p-value assessed with Kruskal–Wallis test.

Figure 8. Relative expression level of key regulatory genes involved in somatotroph cell functioning measured with qRT-PCR in the entire patient cohort, with patients stratified according to three transcriptomic groups. Horizontal dashed line indicates median.

4. Discussion

The symptoms of acromegaly result from GH oversecretion by pituitary tumors which develop from PIT-1-positive anterior pituitary cell lineage. Our results show that the profile of gene expression clearly discriminates somatotroph tumors into three transcriptomic groups that differ in the expression level of a large number of genes. According to GSE results, the expression differences are mainly related to process of cell signaling including G-protein signaling and ion transport, both of which play key roles in regulation of secretory activity of pituitary cells [7,41] as well as to cellular adhesion and differentiation.

Importantly, DEGs include genes directly involved in regulation of GH secretion like those coding for receptors of somatoliberin, gastric inhibitory polypeptide and ghrelin, and receptors for dopamine and somatostatin, as well as voltage-gated calcium channels. It seems that secretory activity in tumors of each transcriptomic subgroup may be driven by a slightly different mechanism. The first group is characterized by high expression of GHRHR, GIPR, and VGCCs as well as the highest expression of GH-encoding gene. The second group includes tumors which seem to be mainly related to hypothalamic GHRH stimulation, as they show high GHRHR expression. Tumors in the third group, in turn, are probably dependent on ghrelin signaling since they present with the highest expression of gene encoding ghrelin receptor.
GIPR, which is highly expressed in group 1 tumors, encodes the receptor of glucose-dependent insulinotropic polypeptide (GIP) that has a well-known role in neuroendocrine tumors [25]. Upon ligand binding GIPR activates coupled heterotrimeric G-protein complex containing a stimulatory G subunit and leads to activation cAMP pathway. Therefore, GIPR activation is considered to be mimicking GHRHR stimulation by hypothalamic GHRH hormone [25]. Acromegaly patients with GIPR expression commonly react to oral glucose load with a paradoxical increase in GH level, which resembles the induction of hormone secretion in food-dependent Cushing’s syndrome [11]. DNA methylation profiling in GIPR-high versus GIPR-low somatotroph PitNETs showed a difference in genome-wide methylation pattern which is in line with our results, indicating that this group represents a separate molecular subtype [12]. Interestingly, high expression of NR5A1 encoding SF-1 transcription factor was found exclusively within this transcriptional group. According to classification of PitNETs, SF-1 is a well-established marker of gonadotroph tumors and the observation that it is also expressed in a particular subtype of somatotroph tumors may suggest a need of slight revision of classification criteria. We observed that GIPR-high somatotroph PitNETs express NR5A1 at the level comparable to gonadotroph tumors. Of note, the expression of NR5A1 in some somatotroph PitNETs was also recently noticed by Mario Neou et al. [42].

The results of our immunohistochemical staining with antibodies against SF-1 and PIT-1 in tumors of transcriptomic subtype 1 clearly show that they are expression-positive for both transcription factors. Nuclear SF-1 immunoreactivity was observed in these tumors, as could be expected in staining of gonadotroph PitNETs according to the most up-to-date diagnostic criteria [43]. The expression of both PIT-1 and SF-1 was previously shown in rare double pituitary adenomas that are composed of multiple PitNETs in one tumor [43,44]. In double PitNETs two areas of tumor tissue with distinct expression of PIT-1 or SF-1 can be observed [44]. In contrary to double tumors our tissue staining of somatotroph PitNETs of transcriptomic group 1 clearly showed the co-expression of PIT-1 and SF-1 over the entire tumor sample area, clearly indicating the homogenous nature of these double-positive somatotroph PitNETs. From a histological point of view, they are unequivocally somatotroph tumors (based on both immunohistochemistry and electron microscopy) [45].

In our study we clearly demonstrated that somatotroph tumors with SF-1 expression are those that express GIPR. It appears to be functionally related. GIPR plays a role in steroidogenesis, as previously observed in adrenal cortex-derived cell line and mice. The experiments showed that manipulating GIPR expression results in changes of transcription levels of NR5A1, STAR, and CYP11A1 [39,40]. Transcriptomic group 1 tumors are those with significantly highest expression of GIPR, NR5A1, STAR, and CYP11A1 as compared to tumors from other groups. Accordingly, correlation analysis indicates that these genes are co-expressed with GIPR. This suggests that high expression level of NR5A1 in transcriptomic group 1 of somatotroph tumors results from high GIPR-related signaling. The mechanism underlying high GIPR expression in somatotroph tumors was the matter of previous research and it is still unclear [12].

High expression of NR5A1 in tumors in transcriptomic group 1 may suggest the potential contamination of tissue samples with normal pituitary tissue. In fact, subtype 1 tumors do express NR5A1, but they do not differ in the expression of other transcription factors specific for pituitary lineages, such as TBX19. If our results would be biased by the presence of normal anterior pituitary, we would expect the difference in the expression of other markers of pituitary lineages. The clearly observed co-expression of PIT-1 and SF-1 in this subtype of somatotroph PitNETs (Figure 5D) also shows that this result of transcriptome-based classification is not biased by normal pituitary. We cannot exclude any potential contamination with normal tissue at sampling procedure but we are convinced that it did not significantly affect the results of our study.

Transcriptomic classification of acromegaly-causing tumors may have clinical implications. The use of SRLs is basic pharmacological treatment for acromegaly patients. Therapy
response and prognosis were previously found to be related to expression of somatostatin receptor genes (SSTR2 and SSTR5) [27,46], genes involved in EMT [26], and those involved in cell proliferation like CDKN1B (p27) [27] or MKI67 (Ki-67) [35]. Loss of cadherin E was clearly linked with a poor response to SRLs [47]. Importantly, striking differences in the expression of CDH1 were observed between transcriptomic groups with the highest expression in group 2 and the lowest in group 3. The expression profile of other genes that were previously shown to be related to SRLs response [27,28,31,33,46] suggests also that tumors in transcriptomic group 2 may be the most sensitive to somatostatin analogs. They have a favorable pattern of gene expression—those related to EMT (high RORC and ESRP1 and low ARRB1 (β-arrestin)) as well as SSTR5 (the highest expression among subtypes), MKI67 (low expression), and CDKN1B (high level).

Preliminary analysis of clinical data from samples included in RNA-seq showed that transcriptomic profile corresponds to pathomorphological diagnosis. In general, transcriptomic group 1 includes GNASwt, densely granulated somatotroph PitNETs, group 2 includes GNASwt and GNASmut DG tumors, and transcriptomic group 3 includes predominantly SG tumors. Unfortunately, the proportions between the pathomorphological subtypes of somatotroph tumors among the samples included in our RNA-seq do not reflect those in general population of acromegaly patients. Therefore, we made an attempt to evaluate the true proportions in patient numbers in individual groups and clinical significance of transcriptomic classification in a large group of acromegaly patients, without any intentional preselection. We evaluated candidate marker genes that allow for stratification of patients into three transcriptomic subtypes and used three most potent markers to classify the entire patient cohort. This classification based on three markers was not adequate only in six patients that were subsequently excluded from the analysis. The results allow some general conclusions to be drawn. They clearly show that in transcriptomic group 1 there are patients with GNASwt, DG tumors (mainly pure somatroph PitNETs but also tumors that are positive for both GH and LH) with low frequency of invasive growth. These tumors are positive for both NR5A1 (SF-1) and GIPR expression and probably include the patients with paradoxical GH response to glucose intake, according to previous studies [11]. These patients are the least frequent and they account for approximately 20% of patients suffering from acromegaly. Transcriptomic group 2 seems to be the most numerous (46% of acromegaly patients). It includes mostly GNASmut, densely granulated tumors as determined with electron microscopy, diagnosed generally as DG somatotroph PitNETs, and additionally mixed GH/PRL tumors. The smaller tumor size found in this group is concordant with the observation that a favorable gene expression profile was observed in these tumors. Accordingly, a low rate of invasive growth was reported for these patients. This corresponds to general observation of better prognosis in patients with densely granulated tumors rather than sparsely granulated tumors [5]. In the third transcriptomic group there are sparsely granulated tumors with a low frequency of GNAS mutations diagnosed mainly as SG somatotroph PitNETs. They account for approximately 35% of tumors causing acromegaly. These tumors have the highest rate of invasive growth and unfavorable gene expression profile (low expression of CDH1, RORC, and ESRP1 and high ARRB1, MKI67, ZEB1, STAT3, and TGFβ1 levels). They also have a high level of DRD1 gene expression, encoding stimulatory dopamine receptor that activates cAMP pathway [48]. This may affect the results of treating these patients with dopamine analogs like cabergoline. In general, the identified gene expression patterns correspond to literature data indicating that patients with sparsely granulated tumors are considered to have high risk tumors [5] as they have worse prognosis, lower rate of postoperative remission, and tumors with frequent invasive growth, a tendency to regrow after surgery, and lower response to SRLs [5]. Our transcriptomic data indicate that these tumors may be significantly driven by ghrelin signaling. They have higher expression of ghrelin receptor gene as compared to densely granulated tumors. The role of ghrelin signaling in GH secretion and pathogenesis of somatotroph PitNETs was already determined [49]. Importantly, the ghrelin receptor was recognized as a therapeutic target [50]. Small inhibitors against this
Cells 2022, 11, 3846

receptor are available and were already subjected to clinical trials on treatment of various human diseases [50]. The use of this therapeutical approach may be potentially beneficial in sparsely granulated tumors with high GHSR expression and it could complement standard treatment with SRLs.

5. Conclusions

Whole-transcriptome analysis revealed three distinct molecular subtypes of somatotroph PitNETs. Each tumor subtype has a distinct molecular profile including gene expression pattern and frequency of GNAS mutations as well as profile of diagnostic histological features based on results of immunohistochemical staining and electron microscopy.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/cells11233846/s1. Figure S1: Overall gene expression profile in somatotroph tumors. Figure S2: Difference in the expression of genes involved in growth hormone (GH) secretion pathway in three subtypes of somatotroph tumors. Figure S3: qRT-PCR-based evaluation of nine genes that potentially serve as marker genes for transcriptional groups of somatotroph tumors. Table S1: Sequences of PCR primers. Table S2: Genes differentially expressed between particular transcriptomic subgroups of somatotroph PitNETs. Table S3: Results of Geneset Enrichment Analysis of genes differentially expressed between particular transcriptomic subgroups of somatotroph PitNETs.

Author Contributions: J.R.: Conceptualization, Methodology, Formal analysis, Investigation, Visualization, Writing—review and editing; P.K.: Formal analysis, Investigation, Writing—original draft preparation; N.R.: Investigation; B.J.M.: Investigation; M.M.: Resources, Data curation, Writing—review and editing; A.N.: Resources, Investigation; S.B.: Writing—review and editing, Formal analysis, Visualization; G.Z.: Resources, Data curation; J.K.: Resources, Data curation; M.B.: Conceptualization, Methodology, Formal analysis, Visualization, Writing—original draft preparation, Funding acquisition. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by Maria Sklodowska-Curie National Research Institute of Oncology, grant number SN/GW04/2020.

Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Ethics Committee of Maria Sklodowska-Curie Institute—Oncology Center in Warsaw, Poland (approval decision 70/2020).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: RNA-Seq data is available at ArrayExpress: E-MTAB-11889 (https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-11889; access date 1 December 2022).

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Melmed, S. Acromegaly. N. Engl. J. Med. 2006, 355, 2558–2573. [CrossRef] [PubMed]
2. Asa, S.L.; Kucharczyk, W.; Ezzat, S. Pituitary Acromegaly: Not One Disease. Endocr Relat Cancer 2017, 24, C1–C4. [CrossRef] [PubMed]
3. Akirov, A.; Asa, S.L.; Amer, L.; Shimon, I.; Ezzat, S. The Clinicopathological Spectrum of Acromegaly. J. Clin. Med. 2019, 8, 1962. [CrossRef] [PubMed]
4. Swanson, A.A.; Erickson, D.; Donegan, D.M.; Jenkins, S.M.; van Gompel, J.J.; Atkinson, J.L.D.; Erickson, B.J.; Giannini, C. Clinical, Biological, Radiological, and Pathological Comparison of Sparsely and Densely Granulated Somatotroph Adenomas: A Single Center Experience from a Cohort of 131 Patients with Acromegaly. Pituitary 2021, 24, 192–206. [CrossRef] [PubMed]
5. Kontogeorgos, G.; Thodou, E.; Osamura, R.Y.; Lloyd, R.V. High-Risk Pituitary Adenomas and Strategies for Predicting Response to Treatment. Hormones 2022, 21, 1–14. [CrossRef]
6. Efstathiadou, Z.A.; Bargiota, A.; Chrisoulidou, A.; Kanakis, G.; Papanastasiou, L.; Theodoropoulou, A.; Tigas, S.K.; Vassiliadi, D.A.; Alevizaki, M.; Tsagarakis, S. Impact of Gsp Mutations in Somatotroph Pituitary Adenomas on Growth Hormone Response to Somatostatin Analogues: A Meta-Analysis. Pituitary 2015, 18, 861–867. [CrossRef]
7. Lania, A.; Spada, A. G-Protein and Signalling in Pituitary Tumours. Horm. Res. 2009, 71, 95–100. [CrossRef]
31. Gatto, F.; Biermasz, N.R.; Feelders, R.A.; Kros, J.M.; Dogan, F.; van der Lely, A.J.; Negrergs, S.J.C.M.M.; Lamberts, S.W.J.; Pereira, A.M.; et al. Low Beta-Arrestin Expression Correlates with the Responsiveness to Long-Term Somatostatin Analogue Treatment in Acromegaly. *Endocr. J.* 2016, 174, 651–662. [CrossRef]

32. Gatto, F.; Feelders, R.; van der Pas, R.; Kros, J.M.; Dogan, F.; van Koetsveld, P.M.; van der Lelij, A.J.; Negrergs, S.J.C.M.M.; Minuto, F.; de Herder, W.; et al. β-Arrestin 1 and 2 and G Protein-Coupled Receptor Kinase 2 Expression in Pituitary Adenomas: Role in the Regulation of Response to Somatostatin Analogue Treatment in Patients with Acromegaly. *Endocrinology* 2013, 154, 4715–4725. [CrossRef]

33. Gil, J.; Marques-Pamies, M.; Valassi, E.; García-Martínez, A.; Serra, G.; Hostalot, C.; Fajardo-Montañana, C.; Currato, C.; Bernabeu, I.; Marazuela, M.; et al. Implications of Heterogeneity of Epithelial-Mesenchymal States in Acromegaly Therapeutic Pharmacologic Response. *Biomedicines* 2022, 10, 460. [CrossRef] [PubMed]

34. Vitali, E.; Peverelli, E.; Giardino, E.; Locatelli, M.; Lasio, G.B.; Beck-Peccoz, P.; Spada, A.; Lania, A.G.; Mantovani, G. Cyclic Adenosine 3'-5'-Monophosphate (CAMP) Exerts Proliferative and Anti-Proliferative Effects in Pituitary Cells of Different Types by Activating Both CAMP-Dependent Protein Kinase A (PKA) and Exchange Proteins Directly Activated by CAMP (Epac). *Mol. Cell. Endocrinol.* 2014, 383, 193–202. [CrossRef] [PubMed]

35. Gil, J.; Marques-Pamies, M.; Jordà, M.; Fajardo-Montañana, C.; García-Martínez, A.; Sampredo, M.; Serra, G.; Salinas, I.; Blanco, A.; Valassi, E.; et al. Molecular Determinants of Enhanced Response to Somatostatin Receptor Ligands after Debulking in Large GH-Producing Adenomas. *Clin. Endocrinol.* 2021, 94, 811–819. [CrossRef] [PubMed]

36. Li, Z.; Li, J.; Shan, X.; Guí, S.; Li, C.; Zhang, Y. Expression of Transforming Growth Factor B1, Smad3, and Phospho-Smad3 in Somatotropinomas and Their Relationship to Tumor Behavior. *World Neurosurgery*. 2021, 153, e20–e27. [CrossRef] [PubMed]

37. Zhou, C.; Jiao, Y.; Wang, R.; Ren, S.G.; Wawrowsky, K.; Melmed, S. STAT3 Upregulation in Pituitary Somatotroph Adenomas Induces Growth Hormone Hypersecretion. *J. Clin. Investig.* 2015, 125, 1692–1702. [CrossRef] [PubMed]

38. Rusetska, N.; Kober, P.; Krol, S.K.; Boresowicz, J.; Maksymowicz, M.; Kunicki, J.; Bonicki, W.; Bujko, M. Invasive and Noninvasive Nonfunctioning Gonadotroph Pituitary Tumors Differ in DNA Methylation Level of Line-1 Repetitive Elements. *J. Clin. Med.* 2021, 10, 560. [CrossRef]

39. Bates, H.E.; Campbell, J.E.; Ussher, J.R.; Baggio, L.L.; Maida, A.; Seino, Y.; Drucker, D.J. Gipr Is Essential for Adrenocortical Steroidogenesis; However, Corticosterone Deficiency Does Not Mediate the Favorable Metabolic Phenotype of Gipr−/− Mice. *Diabetes* 2012, 61, 40–48. [CrossRef]

40. Fujii, H.; Tamamori-Adachi, M.; Uchida, K.; Susa, T.; Nakakura, T.; Hagiwara, H.; Iizuka, M.; Okinaga, H.; Tanaka, Y.; Okazaki, T. Marked Cortisol Production by Intracrine ACTH in GIP-Treated Cultured Adrenal Cells in Which the GIP Receptor Was Exogenously Introduced. *PLoS ONE* 2014, 9, e110543. [CrossRef]

41. Fletcher, P.A.; Sherman, A.; Stoijilkovic, S.S. Common and Diverse Elements of Ion Channels and Receptors Underlying Electrical Activity in Endocrine Pituitary Cells. *Mol. Cell. Endocrinol.* 2018, 463, 23–36. [CrossRef]

42. Neou, M.; Villa, C.; Armignacco, R.; Jouinot, A.; Raffin-Sanson, M.L.; Septier, A.; Letourneur, F.; Diry, S.; Diedisheim, M.; Izac, B.; et al. Pangenomic Classification of Pituitary Neuroendocrine Tumors. *Endocr. Pathol.* 2021, 153(e5), [CrossRef]

43. Asa, S.L.; Mete, O.; Perry, A.; Osamura, R.Y. Overview of the 2022 WHO Classification of Pituitary Tumors. *Endocr. Pathol.* 2022, 33, 6–26. [CrossRef]

44. Jastania, R.A.; Alsaaad, K.O.; Al-Shraim, M.; Kovacs, K.; Asa, S.L. Double Adenomas of the Pituitary: Transcription Factors Pit-1, T-Pit, and SF-1 Identify Cytogenesis and Differentiation. *Endocr. Pathol.* 2005, 16, 187–194. [CrossRef] [PubMed]

45. Asa, S.L. *Tumors of the Pituitary Gland*; American Registry of Pathology Press: Washington, DC, USA, 2011.

46. Iacovazzo, D.; Carlsen, E.; Lugli, F.; Chiloiro, S.; Bianchi, A.; Giampietro, A.; Mormando, M.; Clear, A.J.; Doglietto, F.; et al. Factors Predicting Pasireotide Responsiveness in Somatotroph Pituitary Adenomas Resistant to First-Generation Somatostatin Analogues: An Immunohistochemical Study. *Endocrinology* 2020, 161, 241–250. [CrossRef] [PubMed]

47. Puig-Domingo, M.; Gil, J.; Sampredo-Nuñez, M.; Jordà, M.; Webb, S.M.; Serra, G.; Pons, L.; Salinas, I.; Blanco, A.; Marques-Pamies, M.; et al. Molecular Profiling for Acromegaly Treatment: A Validation Study. *Endocr. Relat. Cancer* 2020, 27, 375–389. [CrossRef] [PubMed]

48. Rosas-Cruz, A.; Salinas-Jazmín, N.; Velázquez, M.A.V. Dopamine Receptors in Cancer: Are They Valid Therapeutic Targets? *Technol. Cancer Res. Treat.* 2021, 20, 15330338211027913. [CrossRef]

49. Devesa, J. The Complex World of Regulation of Pituitary Growth Hormone Secretion: The Role of Ghrelin, Klotho, and Nesfatin 1 in It. *Front. Endocrinol.* 2021, 12, 636403. [CrossRef]

50. Liang, Y.; Yin, W.; Yin, Y.; Zhang, W. Ghrelin Based Therapy of Metabolic Diseases. *Curr. Med. Chem.* 2020, 28, 2565–2576. [CrossRef]